CD4^+CD25^+调节性T细胞在肿瘤免疫中的研究进展  

The progress in CD4^+CD25^+ regulatory T cell and anti-tumor immune research

作　　者：胡子龙[1] 何长征[1] 邢晓伟[1] 胡时栋[1] 李宇轩[1] 宋林杰 王玉锋[2] 杜晓辉[1] HU Zi-long;HE Chang-zheng;XING Xiao-wei;HU Shi-dong;LI Yu-xuan;SONG Lin-jie;WANG Yu-feng;DU Xiao-hui(Department of General Surgery General Hospital of the PLA,Beijing 100853,China;Department of Hospital Management Section,General Hospital of the PLA,Beijing 100853,China)

机构地区：[1]解放军总医院普通外科,北京100853 [2]解放军总医院住院管理科,北京100853

出　　处：《川北医学院学报》2018年第1期134-137,共4页Journal of North Sichuan Medical College

基　　金：国家自然科学基金(61170123)

摘　　要：调节性T细胞(regulatory T cells,Treg细胞)是一类控制体内自身免疫反应的具有免疫抑制功能的T细胞亚群,与自身免疫性疾病的发生、移植耐受、肿瘤的免疫抑制等关系密切。近年来,Treg细胞在肿瘤中的作用研究逐渐成为热点,受到广泛关注。研究发现Treg细胞在肿瘤的发生、发展和转移的过程中发挥重要作用,可通过细胞-细胞接触、分泌抑制性细胞因子、干扰细胞代谢等方式直接或间接影响CD4^+CD8^+效应T细胞的功能,从而抑制机体的抗肿瘤免疫。因此,针对Treg的免疫疗法对于治疗肿瘤具有广阔前景。本文就调节性T细胞的作用机制特点及其与肿瘤免疫的关系做一简要综述。Regulatory T cell(Tregs)is a kind of T cell subsets with immunosuppressive function,which plays a key role in immunotolerance.And it is correlated with autoimmune diseases,transplantation tolerance,and tumor immunologic suppression.Recently,an increasing number of studies focus on the role of Tregs in cancer treatment.It was found that Tregs play a key role in progression and development of human malignant tumors.Tregs can affect the effector T cells and anti-tumor immunity by cell-cell contact,cytokines,and cell metabolism interference.Therefore,the immunotherapy which aims at Tregs can be very useful in treating malignant tumors in future.In this paper,the characteristics of Tregs and its relationship with tumor immunotherapy are reviewed.

关 键 词：CD4+CD25+调节性T细胞 肿瘤免疫 肿瘤治疗 

分 类 号：R730.3[医药卫生—肿瘤]